@nyxygirl

My rheumatologist referenced the GiACTA study for GCA when he requested ACTEMRA (tocilizumab) for me in order to treat PMR.

Actemra is another IL-6 receptor blocker similar to KEVZARA.

The following was documented in my medical records:

Criteria for tocilizumab in Giant Cell Arteritis (GCA) as listed below, most notably the inability to taper steroids. It is believed that PMR is mediated by IL-6 mimicking GCA. PMR therefore would seem most likely to respond to IL-6 blockade with Tocilizumab. Approved for use pending appropriate labs have been obtained. Dosage and administration should follow recommendations for treatment for GCA.

The request is approved:
- A documented therapeutic failure of the preferred formulary alternative(s) exists.

A link to the GiACTA Study:
https://www.nejm.org/doi/full/10.1056/nejmoa1613849
Key Opinion Leader in USA for GCA:
John Stone, MD, MPH
Director Clinical Rheumatology
Massachusetts General Hospital